市場調查報告書
商品編碼
1150349
失眠全球市場規模、份額和行業趨勢分析報告:按分銷渠道(醫院、零售、其他)、治療類型(藥物、非藥物)、區域展望和預測2022-2028Global Insomnia Market Size, Share & Industry Trends Analysis Report By Distribution Channel (Hospital, Retail, and Others), By Therapy Type (Pharmacological and Non-Pharmacological), By Regional Outlook and Forecast, 2022 - 2028 |
在預測期內,全球失眠市場規模預計將以 3.9% 的複合年增長率增長,到 2028 年將達到 57 億美元。
由於工作相關壓力的增加,失眠市場正在增長。增加的工作量和苛刻的工作時間表會導致睡眠不足。此外,包括保安人員在內的許多人都在不定期輪班工作,並且生產全天候開放。這些不規律的輪班會影響睡眠的質量和節奏。近年來,睡眠診斷和失眠症中心的數量也有所增加。失眠中心幫助人們獲得更好的睡眠質量,睡眠障礙中心充當診斷實驗室。
COVID-19 影響分析
COVID-19的爆發有望利好失眠藥物的市場拓展。 Covid-19 大流行使行業陷入癱瘓,使許多工人失業,並加劇了社會壓力水平。其他人則因害怕大流行病而患上抑鬱症。因此,預計 COVID-19 大流行將增加因壓力和抑鬱引起的失眠的發生率,增加對失眠藥物的需求並擴大市場。
市場增長因素
人口老齡化加劇
研究表明,老年人(65 歲以上)患某些類型癌症的可能性是年輕人的 11 倍。未來 20 年,隨著世界人口老齡化,老年人的癌症發病率預計會增加。屈光不正、白內障、睡眠問題和聽力損失在老年人中都很常見。在全球範圍內,許多老年人都有睡眠問題。因此,預計人口老齡化將導致失眠病例數量增加,進一步推動預測期內失眠市場的增長。
不斷上漲的醫療費用
由於對治療方案的認識提高,醫療保健成本上升和疾病的早期診斷預計將成為預測期內推動市場增長的因素。政府在醫療保健行業投資的規模和數量不斷增加也是推動市場增長的關鍵因素之一。隨著 COVID-19 大流行的開始,許多政府加大了對建設醫療保健系統的投資。隨著大流行的影響減弱,各家醫院都將這些資源集中在治療其他嚴重疾病上。由於醫療保健投資的增加,失眠市場正在增長。
市場製約因素
診斷和治療失眠的費用
診斷和治療失眠症的高成本是阻礙失眠症市場增長的主要因素之一。 “睡眠障礙”一詞還包括一系列對個人健康有重大負面影響並產生高社會成本的疾病。失眠使人難以過上正常的生活,經濟和醫療負擔也很大,許多患者甚至會完全殘疾。失眠患者每年直接在醫療保健上的花費是無症狀對照組的兩倍左右。由於藥價高,失眠市場沒有增長。
按分銷渠道劃分的前景
失眠藥物市場按分銷渠道分為醫院、零售和其他。 2021 年,零售部門在失眠市場的銷售額中佔據了相當大的份額。由於各種零售店廣泛供應睡眠障礙治療藥,這一領域的市場正在增長。此外,人們對失眠等疾病後果的認識不斷提高,也推動了這一市場的發展。政府還支持在這些商店出售的安眠藥。
治療類型的前景
根據治療類型,失眠市場分為非藥物療法和藥物療法。 2021年,藥物治療板塊主導失眠市場,收入佔比最大。這是由於失眠症患病率的上升以及失眠藥物的主要製造商數量的增加。失眠藥物和安眠藥的存在正在全世界蔓延。在這個領域,由於世界各地有許多市場參與者,市場規模正在增長。
區域概覽
按地區分析了北美、歐洲、亞太地區和 LAMEA 的失眠市場。 2021 年,北美地區在失眠市場的收入份額最高。這是由於醫療保健系統的發展,包括失眠症患病率增加、工作壓力大以及該地區失眠中心的存在。慢性腎病患者數量的增加以及該地區大量失眠診所的存在預計也將推動市場增長。
The Global Insomnia Market size is expected to reach $5.7 billion by 2028, rising at a market growth of 3.9% CAGR during the forecast period.
A common sleep disorder called insomnia can make it difficult to fall asleep, stay asleep, or wake up early and have trouble falling back asleep. Stress, bad sleeping habits, irregular sleep schedules, mental health conditions like physical illnesses and pain, anxiety and depression, medications, neurological issues, and specific sleep disorders are some of the common causes of insomnia.
The rise in the prevalence of distinct sleep disorders, including parasomnias as well as insomnia, and the rise in mental depression and other painful conditions, are the main factors driving the growth of the insomnia market size. Sleep issues are a result of mental depression. As a result, an increase in mental depression among the general population contributes to the growth of the insomnia market. Furthermore, taking some medications for a chronic condition over an extended period of time has some side effects that are thought to impair a patient's ability to sleep.
Additionally, the market for insomnia is expanding due to an increase in work-related stress. The increased workload and demanding work schedules result in poor sleep. Additionally, a lot of people including security guards work odd shifts, and the manufacturing sector is open around-the-clock. The quality and rhythm of sleep are impacted by these irregular work shifts. Also, a rise in the number of sleep diagnostics and centres for people with insomnia helps has been seen in the past few years. The centres for insomnia help people get better quality sleep, and the centres for sleep disorders are utilized as diagnostic testing facilities.
COVID-19 Impact Analysis
It is anticipated that the COVID-19 outbreak will benefit the expansion of the market for insomniac remedies. Due to improperly functioning industries brought on by the COVID-19 pandemic, many workers lost their jobs, which contributed to an increase in stress levels in society. Additionally, some people around the world developed depression as a result of pandemic fear. As a result, the COVID-19 pandemic's increased incidence of insomnia a condition marked by stress and depression boosts the demand for drugs that treat insomnia and propel the market's expansion.
Market Growth Factors
Increasing Aging Population
According to studies, older people (defined as those 65 and older) appear to have an 11-fold increased risk of developing some types of cancer than younger people. The burden of cancer among the elderly would then increase as the world population ages over the following 20 years. Refractive errors, cataracts, sleep issues, and hearing loss are all fairly common in older people. A large ratio of old age people is facing sleeping issues worldwide. Thus, the rise in the aging population would result in an increasing number of insomnia cases which would further support the growth of the insomnia market over the forecast period.
Increasing Healthcare Costs
Rising healthcare costs and earlier disease diagnosis because of greater awareness of treatment options are factors that are anticipated to fuel the market growth over the course of the forecast period. The increasing size and number of funds invested in the healthcare industry by governments of different countries are one of the primary drivers of the market's growth. Governments from a number of nations boosted their investments in creating healthcare systems whenever the COVID-19 pandemic first started to spread. As the pandemic's impact lessens, various hospitals are now concentrating on using these resources to treat other severe diseases. The insomnia market is expanding as a result of rising healthcare investment.
Market Restraining Factors
High Cost Of Diagnosing And Treating Insomnia
The high cost of diagnosis and treatment is one of the major factors impeding the growth of the insomnia market. Additionally, the term "sleeping problem" covers a wide range of illnesses that have significant detrimental effects on an individual's health and incur high societal costs. Insomnia makes it difficult to carry out daily tasks and is associated with a heavy financial & medical burden many patients are completely disabled. Insomnia patients spent about two times as much on direct medical care each year as matched controls without condition. The market for insomnia is not expanding because of the high cost of the medication.
Distribution Channel Outlook
By distribution channel, the insomnia market is divided into hospital, retail and others. The retail segment recorded a substantial revenue share in the insomnia market in 2021. The market in this segment is growing as a result of the wide availability of pills for treatment of sleeping disorder in various retail stores. In addition, the market is also growing due to rising awareness of consequences of diseases such as insomnia. Also, the government is supporting the medicines for condition to be marketed in such stores.
Therapy Type Outlook
Based on therapy type, the insomnia market is segmented into non-pharmacological therapy, pharmacological therapy. In 2021, the pharmacological therapy segment dominated the insomnia market with the maximum revenue share. This is due to the rising prevalence of insomnia and the growing number of major manufacturers of therapeutic drugs for insomnia. The presence of pills for insomnia treatment and sleeping pills is wide all over the world. The market is expanding in this segment as a result of a large number of market players present all over the world.
Regional Outlook
Region wise, the insomnia market is analyzed across the North America, Europe, Asia Pacific and LAMEA. In 2021, the North America region held the highest revenue share in the insomnia market. This is due to an increase in the prevalence of insomnia, a high incidence of stress at work, and a developed healthcare system, including the presence of insomnia centers in the region. Additionally, a rise in the number of patients suffering from chronic renal and kidney illnesses as well as the existence of a sizable number of insomnia clinics in this region are predicted to fuel market growth.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Currax Pharmaceuticals LLC (Currax Holdings USA LLC), Eisai Co., Ltd., Merck Group, Pfizer, Inc., Vanda Pharmaceuticals, Inc., Cadila Healthcare Ltd. (Zydus Cadila), Sanofi S.A., Viatris, Inc., Takeda Pharmaceutical Company Limited, and Purdue Pharma L.P.
Strategies deployed in Insomnia Market
Oct-2021: Currax expanded its geographical footprints in Brentwood by opening HQ in the region. This expansion aimed at expanding access to medicines, both generic and brand name.
Dec-2020: Vanda Pharmaceuticals got FDA approval for the HETLIOZ capsule & liquid formulation, the first FDA-approved medication for patients with SMS. The product would be used for the treatment of adults & children, respectively, with nighttime sleep disturbances associated with Smith-Magenis Syndrome (SMS).
Jun-2020: Sanofi expanded its geographical footprint in India. This expansion focused on producing Amaryl & Daonil tablets for blood glucose reduction, Frisium for seizures, and Stilnoct for insomnia in the region.
Jun-2020: Eisai launched DAYVIGO CIV, the in-house discovered orexin receptor antagonist. This launch would address adults with insomnia, characterized by difficulties with sleep onset and sleep maintenance.
Dec-2019: Eisai got FDA approval for DAYVIGO. Through this approval, DAYVIGO would be commercially available in 5 mg and 10 mg tablets following scheduling by the U.S. Drug Enforcement Administration (DEA), which is expected to occur within 90 days.
Sep-2019: Currax signed an agreement to acquire Nalpropion Pharmaceuticals, a biopharmaceutical company focused on the treatment of weight loss. This acquisition enables Currax to own the worldwide rights to CONTRAVE, one of the most prescribed weight-loss brand medications in the US.
Sep-2019: Takeda and Lundbeck got Labour and Welfare (MHLW) approval of Trintellix. By this approval, Trintellix would be able to provide the treatment of depression and depressed state.
Jul-2019: Zydus Cadila introduced Ramelteon tablets, USFDA-approved capsules used to treat insomnia. Ramelteon would be used in the treatment of insomnia associated with having trouble falling asleep.
Market Segments covered in the Report:
By Distribution Channel
By Therapy Type
By Geography
Companies Profiled
Unique Offerings from KBV Research
List of Figures